In 1315 ER+ patients, regardless of HER2 status, that received chemotherapy as part of their primary breast cancer treatments, 564 (42.9%) had died by the end of the study follow-up period, of which 334 (59.2%) were recorded as caused by breast cancer (Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.